

Alexandra Calmy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2939700/publications.pdf>

Version: 2024-02-01

110
papers

3,722
citations

136885

32
h-index

149623

56
g-index

115
all docs

115
docs citations

115
times ranked

5562
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. <i>Clinical Infectious Diseases</i> , 2022, 74, 1468-1475.	2.9	3
2	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	0.9	69
3	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 492-499.	1.3	7
4	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1592-1600.	1.9	4
5	Impact of Latent Tuberculosis on Diabetes. <i>Journal of Infectious Diseases</i> , 2022, 225, 2229-2234.	1.9	3
6	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	0.9	0
7	Cardiovascular risk assessment in people living with HIV compared to the general population. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 689-699.	0.8	12
8	Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial. <i>Clinical and Translational Science</i> , 2022, 15, 1796-1804.	1.5	6
9	Accelerating investigation of new HIV drugs in pregnancy: advancing the research agenda from theory to action. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	6
10	Approaches to accelerating the study of new antiretrovirals in pregnancy. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	7
11	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2021, 73, e2134-e2141.	2.9	23
12	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1413-1421.	2.9	2
13	Cyber harassment of female scientists will not be the new norm. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 457-458.	4.6	4
14	Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis. <i>Nature Communications</i> , 2021, 12, 1219.	5.8	2
15	The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland. <i>International Journal of STD and AIDS</i> , 2021, 32, 729-739.	0.5	5
16	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	2.0	66
17	Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland. <i>PLoS ONE</i> , 2021, 16, e0246579.	1.1	3
18	Prophylaxis for COVID-19: a systematic review. <i>Clinical Microbiology and Infection</i> , 2021, 27, 532-537.	2.8	21

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4455-4460.	1.1	0
20	Network Analysis of Outpatients to Identify Predictive Symptoms and Combinations of Symptoms Associated With Positive/Negative SARS-CoV-2 Nasopharyngeal Swabs. <i>Frontiers in Medicine</i> , 2021, 8, 685124.	1.2	5
21	Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. <i>Aids</i> , 2021, Publish Ahead of Print, 2469-2480.	1.0	6
22	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 295.	1.0	11
23	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment—Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	2.9	16
24	Caring for people living with HIV during the global coronavirus disease 2019 pandemic. <i>Aids</i> , 2021, 35, 355-358.	1.0	5
25	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. <i>EClinicalMedicine</i> , 2021, 42, 101188.	3.2	5
26	Weight gain stopping/switch rules for antiretroviral clinical trials. <i>Aids</i> , 2021, 35, S183-S188.	1.0	15
27	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. <i>Clinical Infectious Diseases</i> , 2020, 70, 297-303.	2.9	10
28	Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. <i>EClinicalMedicine</i> , 2020, 28, 100573.	3.2	54
29	Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. <i>Lancet HIV</i> , 2020, 7, e677-e687.	2.1	86
30	Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa438.	0.4	4
31	Dexamethasone and remdesivir: finding method in the COVID-19 madness. <i>Lancet Microbe</i> , 2020, 1, e309-e310.	3.4	18
32	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020, 11, 5542.	5.8	5
33	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 224, 1198-1208.	1.9	5
34	HIV and antiretroviral therapy-related fat alterations. <i>Nature Reviews Disease Primers</i> , 2020, 6, 48.	18.1	104
35	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.	1.9	22
36	Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. <i>Journal of the International AIDS Society</i> , 2020, 23, e25489.	1.2	116

#	ARTICLE	IF	CITATIONS
37	Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. <i>Lancet HIV</i> , 2020, 7, e193-e200.	2.1	41
38	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 240-250.	0.9	24
39	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz464.	0.4	7
40	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLA™ HIV trial. <i>PLoS Medicine</i> , 2020, 17, e1003421.	3.9	23
41	Differences in Social and Mental Well-Being of Long-Term Survivors among People who Inject Drugs and Other Participants in the Swiss HIV Cohort Study: 1980â€“2018. <i>Antiviral Therapy</i> , 2020, 25, 43-54.	0.6	2
42	Title is missing!. , 2020, 17, e1003421.		0
43	Title is missing!. , 2020, 17, e1003421.		0
44	Title is missing!. , 2020, 17, e1003421.		0
45	Title is missing!. , 2020, 17, e1003421.		0
46	Title is missing!. , 2020, 17, e1003421.		0
47	Title is missing!. , 2020, 17, e1003421.		0
48	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz330.	0.4	28
49	Dolutegravir-Based or Low-Dose Efavirenzâ€“Based Regimen for the Treatment of HIV-1. <i>New England Journal of Medicine</i> , 2019, 381, 816-826.	13.9	196
50	Mortality from suicide among people living with HIV and the general Swiss population: 1988â€“2017. <i>Journal of the International AIDS Society</i> , 2019, 22, e25339.	1.2	24
51	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 834.	1.3	6
52	Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2468-2470.	1.3	3
53	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. <i>Journal of Infectious Diseases</i> , 2019, 220, 244-253.	1.9	6
54	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. <i>Journal of Infectious Diseases</i> , 2019, 220, 254-265.	1.9	27

#	ARTICLE	IF	CITATIONS
55	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. <i>Journal of the International AIDS Society</i> , 2019, 22, e25402.	1.2	7
56	Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient. <i>Annals of Hematology</i> , 2019, 98, 1317-1318.	0.8	1
57	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2019, 6, e116-e127.	2.1	84
58	Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz277.	0.4	20
59	Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African Countries. <i>JMIR MHealth and UHealth</i> , 2019, 7, e13741.	1.8	6
60	Will NNRTIs be driving forward again?. <i>Lancet HIV</i> , 2018, 5, e200-e201.	2.1	5
61	Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. <i>European Heart Journal</i> , 2018, 39, 2147-2154.	1.0	47
62	Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. <i>Clinical Infectious Diseases</i> , 2018, 66, 1099-1108.	2.9	24
63	Benefits and risks of rapid initiation of antiretroviral therapy. <i>Aids</i> , 2018, 32, 17-23.	1.0	191
64	Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. <i>F1000Research</i> , 2018, 7, 1359.	0.8	31
65	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. <i>Virus Evolution</i> , 2018, 4, vey024.	2.2	17
66	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. <i>Molecular Biology and Evolution</i> , 2018, 35, 27-37.	3.5	37
67	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018, 561, 406-410.	13.7	47
68	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy078.	0.4	8
69	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	4.2	29
70	Universal test and treat is not associated with suboptimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial. <i>Journal of the International AIDS Society</i> , 2018, 21, e25112.	1.2	34
71	Expert consensus statement on the science of HIV in the context of criminal law. <i>Journal of the International AIDS Society</i> , 2018, 21, e25161.	1.2	59
72	Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. <i>F1000Research</i> , 2018, 7, 1359.	0.8	24

#	ARTICLE	IF	CITATIONS
73	Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients. <i>Journal of Infection</i> , 2018, 76, 186-195.	1.7	12
74	A buyersâ€™ club to improve access to hepatitis C treatment for vulnerable populations. <i>Swiss Medical Weekly</i> , 2018, 148, w14649.	0.8	6
75	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1275-1278.	2.9	23
76	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017, 66, 297-303.	1.8	101
77	Virological Outcomes of Second-line Protease Inhibitorâ€‘Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1006-1016.	2.9	37
78	Life expectancy in HIV-positive persons in Switzerland. <i>Aids</i> , 2017, 31, 427-436.	1.0	193
79	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 399-402.	1.9	47
80	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016, 22, 1260-1267.	15.2	133
81	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1310-1317.	2.9	52
82	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 115-122.	2.9	60
83	Switch to etravirine for <sc>HIV</sc>-positive patients receiving statin treatment: a prospective study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 720-730.	1.7	5
84	Is monotherapy maintenance the way forward?. <i>Lancet HIV</i> , 2015, 2, e402-e403.	2.1	1
85	HIV and Ebola virus. <i>Aids</i> , 2015, 29, 1593-1596.	1.0	2
86	Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS). <i>PLoS ONE</i> , 2015, 10, e0140943.	1.1	40
87	Mesenterial involvement of <i>Mycobacterium genavense</i> infection: hard to find, hard to treat. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208241-bcr2014208241.	0.2	5
88	Increases in Condomless Sex in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv077-ofv077.	0.4	35
89	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. <i>BMC Infectious Diseases</i> , 2015, 15, 382.	1.3	29
90	Nevirapine or efavirenz for tuberculosis and HIV coinfecting patients: exposure and virological failure relationship*. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 225-232.	1.3	24

#	ARTICLE	IF	CITATIONS
91	Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review. <i>Clinical Infectious Diseases</i> , 2015, 60, S170-S176.	2.9	35
92	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2015, 212, 578-584.	1.9	20
93	HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. <i>BMC Gastroenterology</i> , 2015, 15, 79.	0.8	18
94	Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. <i>Lancet HIV</i> , 2015, 2, e438-e444.	2.1	227
95	The future role of CD4 cell count for monitoring antiretroviral therapy. <i>Lancet Infectious Diseases</i> , 2015, 15, 241-247.	4.6	115
96	Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals. <i>Current Vascular Pharmacology</i> , 2015, 13, 167-172.	0.8	3
97	Disentangling Human Tolerance and Resistance Against HIV. <i>PLoS Biology</i> , 2014, 12, e1001951.	2.6	53
98	Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2013, 13, 303-312.	4.6	46
99	Persistent Difficulties in Switching to Second-Line ART in Sub-Saharan Africa – A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e82724.	1.1	43
100	Incidence of Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome and Impact on Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e84585.	1.1	22
101	Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. <i>Aids</i> , 2012, 26, 2079-2086.	1.0	47
102	Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. <i>BMC Infectious Diseases</i> , 2012, 12, 147.	1.3	7
103	Higher Memory Responses in HIV-Infected and Kidney Transplanted Patients than in Healthy Subjects following Priming with the Pandemic Vaccine. <i>PLoS ONE</i> , 2012, 7, e40428.	1.1	11
104	HIV treatment for prevention. <i>Journal of the International AIDS Society</i> , 2011, 14, 28-28.	1.2	30
105	HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. <i>Aids</i> , 2009, 23, 929-939.	1.0	130
106	A new era of antiretroviral drug toxicity. <i>Antiviral Therapy</i> , 2009, 14, 165-79.	0.6	21
107	A new era of antiretroviral drug toxicity. <i>Antiviral Therapy</i> , 2009, 14, 165-179.	0.6	47
108	Adherence to Antiretroviral Therapy Assessed by Drug Level Monitoring and Self-Report in Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 216-219.	0.9	25

#	ARTICLE	IF	CITATIONS
109	HIV Viral Load Monitoring in Resource-Limited Regions: Optional or Necessary?. <i>Clinical Infectious Diseases</i> , 2007, 44, 128-134.	2.9	226
110	Early assessment of antiretroviral efficacy is critical to prevent the emergence of resistance mutations in HIV-tuberculosis coinfecting patients: a substudy of the CARINEMO-ANRS12146 trial. <i>F1000Research</i> , 0, 8, 169.	0.8	0